IDWP in 2021

**MAYOR ACHIEVEMENTS**

This year, like 2020, was marked by the SARS-CoV-2 pandemic, impacting all aspects of HSCT, forcing historical changes like the universal cryopreservation of allogenic products in many centres, decreasing the transplant activity for the first time in 30 years (6.5% in allogenic HSCT and 7.5% in auto HSCT) (Passweg JR et al., BMT 2022 in press) and producing an important suffer for our patients with a high rate of mortality.

This year was also marked by the collaboration and generosity of the EBMT family and by a significant increase in the activity of the IDWP. The IDWP has participated in the elaboration of several recommendations and guidelines for this infection with other WPs and groups: the EBMT recommendations for the general management (16 updates) and vaccination of SARS-CoV-2 (8 updates); EBMT recommendations for HSCT in autoimmune diseases in the time of COVID-19 (in collaboration with ADWP /PB/EBMT Nurses Group); and in the ECIL 9 COVID-19 guidelines (manuscript in preparation). Thanks to the generosity of several WPs of EBMT, an extra budget was obtained to support several studies under the umbrella of the recently created COVID Task Force.

But the activity of the IDWP has not been limited to SARS-CoV-2, and many other activities and studies have been done or are in progress. In 2021 we had 17 publications (Leukemia 2; Lancet Oncol 2; CID 1; J Infect 2; Ann Hematol 1; BMT 9) with the highest impact factor in the history of the group (168), and 4 communications to congresses (EBMT and ASH). We also organized two educational courses.

**EDUCATIONAL COURSES IN 2021**

24rd IDWP educational (24 – 26 November 2021)

Covid-19 summit (29 June-1 July 2021)

**PRINCIPLE RESEARCH STUDIES**


*still recruiting

**SEE ALL THE STUDIES ON:** [www.ebmt.org/research/studies](http://www.ebmt.org/research/studies)

**Key Publications 2021**


**SEE ALL PUBLICATIONS ON:** [www.ebmt.org/research/publications](http://www.ebmt.org/research/publications)

IDWP in 2022

**STUDIES STARTING SOON**

**COVID-19 STUDIES:**
2. Prolonged shedding of SARS-CoV-2 infection.
3. Cycle threshold values.
4. Pulmonary imaging

**NON-COVID RETROSPECTIVE:**
1. Infections after HCT in patients with preexisting diabetes mellitus.
2. Non-Tuberculous Mycobacterial Infections after HSCT.
3. Fusarium infections in HSCT recipients.
4. Survey on the use of non-cryopreserved hematopoietic stem cells for auto-HSCT

**NON-COVID PROSPECTIVE:**
- Viral infections after unmanipulated allo-HSCT in pediatric patients.

**IDWP AT 47TH ANNUAL MEETING OF EBMT (VIRTUAL):**

**IDWP BUSINESS MEETING**
Monday, March 21, 7:00-8:50

**IDWP WP SESSION**
Monday, March 21, 9:00-10:15

1. The most important articles on infections in HSCT recipients. M. Mikulska.
2. What’s new in the field of antifungals?. J. Maertens
3. Is antibacterial/antifungal/antiviral prophylaxis needed in CART? L. Gil

**ORAL PRESENTATIONS:**
1. J. Styczynski - Causes of deaths after hematopoietic cell transplantation in the context of lethal infectious complications: IDWP EBMT CID-2 study (OS04-01)
2. D. Averbuch - Listeria infection in hematopoietic cell transplant recipients: an international case-control study of the IDWP of the EBMT (OS04-02)
3. J. L. Pihlana - Upper and/or lower respiratory tract infection caused by human metapneumovirus after allogeneic stem cell transplantation (OS04-08)

**OTHER INFECTION RESEARCH STUDIES**
1. Therapy of fungal infections (MTE-02; Meet the expert). D. Averbuch; 17:00-18:00
2. Mycobacterial infections (MTE-03; Meet the expert). A. Bergeron; 17:00-18:00
3. NG06 – Infections
4. Novel viral infections in immunocompromised patients (MTE-09). M. Von Lilienfeld-Toal; 17:45-18:45
5. COVID-19 in HCT candidates and patients in the post-vaccine era (MTE-14). P. Ljungman
6. OS04 - Oral session 4: Infectious complications I
7. OS06 - Oral session 6: Infectious complications II
8. WS6 - Can we limit infectious complications in transplant setting?
9. E11 - CMV – still a challenge?
10. E12 - Update on viral infections in the transplant setting
11. SS2 - COVID-19
12. NG17 – COVID

**POSTERS:**
1. Handling of allogeneic related and unrelated HPC grafts during the covid-19 pandemic – a survey from the IDWP and CTWP
2. The management of cytomegalovirus infection among EBMT centers: a survey from IDWP of EBMT
3. Outcome of post-vaccination covid-19 in HSCT and CAR T cell treatment recipients; results from an IDWP prospective survey.

**EDUCATIONAL ACTIVITIES IN 2022**

25th IDWP Educational Course –November 3-5, Florence, Italy

**Contact the IDWP**

For participation in, or information regarding IDWP studies, please contact us at

idwp.ebmt@lumc.nl

**FIND MORE INFO ON:**
[ebmt.org/workings-parties/infectious-diseases-working-party-idwp](http://ebmt.org/workings-parties/infectious-diseases-working-party-idwp)